STOCK TITAN

VASO CORPORATION - VASO STOCK NEWS

Welcome to our dedicated page for VASO CORPORATION news (Ticker: VASO), a resource for investors and traders seeking the latest updates and insights on VASO CORPORATION stock.

Vaso Corporation is a diversified medical technology company with specialties in managed IT systems, healthcare software solutions, network connectivity services, professional sales services for medical equipment, and the design, manufacture, and sale of proprietary medical devices. The company operates through three wholly owned subsidiaries, offering a comprehensive range of products and services. Vaso recently reported its operating results for the third quarter of 2023, demonstrating solid year-to-date financial performance despite slight declines in quarterly revenue and profit. With a strong balance sheet, positive operating cash flow, and a history of cyclical revenue growth, Vaso remains optimistic about its future performance. The company is also in the process of uplisting to the Nasdaq Stock Market via a business combination with Achari Ventures Holdings Corp. I, further expanding its market presence and potential for growth.

Rhea-AI Summary

Vaso (OTCQX: VASO), a company focused on human capital, information technology, and MedTech sectors, has released a shareholder and employee letter on December 16, 2024. The letter outlines the company's achievements throughout the year and presents strategic developments and priorities for 2025. The communication covers operational developments, product updates, financial performance, and thought-leadership initiatives, with details available on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.06%
Tags
none
-
Rhea-AI Summary

Vaso (OTCQX: VASO) reported Q3 2024 financial results with revenue of $20.8 million, up 7% from $19.4 million in Q3 2023, driven by growth in network services. However, the company recorded an operating loss of $1.4 million compared to operating income of $907,000 in Q3 2023. The company maintains a strong balance sheet with $26.8 million in cash and investments, and generated $3.6 million in operating cash flow during the first nine months. Deferred revenue increased by $1.4 million to $33.1 million. The net loss for Q3 2024 was $1.2 million, compared to net income of $1.2 million in Q3 2023, primarily due to business combination costs of $1.5 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
-
Rhea-AI Summary

Vaso (OTCQX: VASO) has announced the termination of its Business Combination Agreement with Achari Ventures Holdings Corp. I. The company, based in Plainview, N.Y., made this decision on September 18, 2024. Vaso stated that it will continue to pursue opportunities to enhance stockholder value through various means, including:

  • Internal growth
  • New partnerships
  • Strategic investments

The company's focus will remain on medical and IT service companies as it seeks to expand its business and create value for shareholders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.83%
Tags
none
Rhea-AI Summary

Vaso (OTCQX: VASO) has announced a change in the date of its special stockholders meeting. Originally scheduled for August 26, 2024, the meeting has been adjourned without considering any proposals. The new date is set for September 10, 2024, at 10:00 AM Eastern. The location remains the same: the Lever House at 390 Park Avenue, New York, NY 10022.

The company stated that this postponement, occurring after the Labor Day holiday, is intended to provide more stockholders with the opportunity to attend the meeting in person. This decision reflects Vaso's commitment to maximizing shareholder participation in important corporate decisions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.7%
Tags
none
-
Rhea-AI Summary

Vaso (OTCQX: VASO) reported its Q2 2024 financial results, with total revenue of $20.2 million, slightly down from $20.3 million in Q2 2023. The company's IT segment saw a 1% increase, while the professional sales service segment remained flat. The equipment segment experienced a 30% decrease. Gross profit decreased by 4% to $12.2 million. Net income for Q2 2024 was $1.2 million, down from $2.0 million in Q2 2023. Adjusted EBITDA was $1.2 million, compared to $2.1 million a year ago.

Despite lower earnings, Vaso maintains a strong financial position with $25.7 million in cash and cash equivalents. The company's deferred revenue stands at $31.7 million, with a multi-year high backlog of $39.4 million in the IT segment, indicating potential for future growth. Vaso is pursuing a NASDAQ listing through a proposed business combination with Achari Ventures Holdings Corp. I, with a special stockholders meeting scheduled for August 26, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Vaso (OTCQX: VASO) announced the SEC's approval of Achari Ventures Holdings Corp. I's (NASDAQ: AVHI) S-4 Registration Statement for their proposed business combination. Post-merger, the company will be renamed Vaso Holdings Corp. and listed on NASDAQ. Current Vaso stockholders will own 94-96% of the new entity, valued at approximately $176 million at closing.

Dr. Jun Ma, Vaso's President and CEO, highlighted the company's recent financial performance: annual revenues of $75.2M, $79.3M, and $81.0M in 2021, 2022, and 2023, respectively, with operating incomes of $2.5M, $6.5M, and $4.2M. The company has cash reserves of about $25 million. A special stockholders meeting is scheduled for August 26, 2024, to approve the business combination.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.7%
Tags
none
Rhea-AI Summary

Vaso (OTCQX: VASO) announced its financial results for Q1 2024. Total revenue was $18.7 million, a 1.6% decrease year-over-year primarily due to lower equipment sales. Gross profit fell by 5.6% to $10.9 million, while SG&A expenses rose by 9.4% to $12.2 million. The company reported a net loss of $1.2 million and an adjusted EBITDA of negative $1.3 million. Despite these losses, Vaso's operating cash flow improved by $0.8 million year-over-year, and the company maintained a strong financial position with $26.0 million in cash and short-term investments as of May 3, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.11%
Tags
-
Rhea-AI Summary
Vaso achieves another record in annual revenue, reaching $81.0 million in 2023, a 2.2% increase year-over-year. Net income for the year was $4.8 million, despite significant investments. The Company generated positive cash flow of $5.3 million in 2023. Deferred revenue increased to $32.2 million. Vaso entered into a business combination agreement with Achari Ventures Holdings Corp. I, anticipating a merger and a name change to 'Vaso Holdings Corp.' The Business Combination Agreement values Vaso at approximately $176 million. Financial results for Q4 2023 show a decrease in revenue by 5.6% to $21.9 million, with lower revenues in all segments. Net income for Q4 was $1.1 million, a decrease from the previous year. For the year ended December 31, 2023, revenue increased by 2.2% to $81.0 million. Gross profit increased by 5.6% to $50.6 million, while net income was $4.8 million, a decrease from the previous year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.45%
Tags
-
Rhea-AI Summary
Vaso Corporation (OTCQX:VASO) is merging with Achari Ventures Holdings Corp. I (NASDAQ:AVHI) to uplist to the Nasdaq Stock Market. The transaction values Vaso at a pro forma equity value of approximately $176 million at $10 per share. Upon closing, existing Vaso shareholders will receive consideration consisting entirely of shares of the surviving public combined company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
52.38%
Tags
Rhea-AI Summary
Vaso Corporation (OTCQX:VASO) Reports $19.4 Million Revenue and $1.2 Million Net Income for Q3 2023, Continues Profitability Streak. Despite a slight decrease in revenue and net income for the quarter, year-to-date results show solid growth with $59.1 million in revenue and $3.7 million in net income. The Company maintains a strong balance sheet with $26.9 million in cash, cash equivalents, and short-term investments at the end of Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.75%
Tags

FAQ

What is the current stock price of VASO CORPORATION (VASO)?

The current stock price of VASO CORPORATION (VASO) is $0.120805 as of December 24, 2024.

What is the market cap of VASO CORPORATION (VASO)?

The market cap of VASO CORPORATION (VASO) is approximately 22.8M.

What are Vaso Corporation's core specialties?

Vaso Corporation specializes in managed IT systems, healthcare software solutions, network connectivity services, professional sales services for medical equipment, and the design, manufacture, and sale of proprietary medical devices.

What recent financial results has Vaso Corporation reported?

Vaso recently reported solid year-to-date financial performance for the nine-month period ended September 30, 2023, with revenue increasing to $59.1 million and net income rising to $3.7 million compared to the corresponding nine months of 2022.

What is Vaso Corporation's outlook for the remainder of the year?

Vaso Corporation is cautiously optimistic about its performance for the remainder of the year, historically experiencing higher revenue and income in the fourth quarter due to the cyclical nature of its business.

What is the company's plan regarding uplisting to the Nasdaq Stock Market?

Vaso Corporation is planning to uplist to the Nasdaq Stock Market via a business combination with Achari Ventures Holdings Corp. I, with common stock and warrants expected to be listed under the ticker symbols 'VASO' and 'VASOW', respectively.

How does Vaso Corporation aim to drive future growth and market expansion?

Through its diverse range of products and services, strong financial performance, and strategic initiatives like the uplisting to the Nasdaq Stock Market, Vaso Corporation aims to drive future growth and expand its market presence.

Who is leading Vaso Corporation through its business combination and uplisting process?

Vaso Corporation is led by Chief Executive Officer Jun Ma, who will continue to lead the combined company following the proposed business combination with Achari Ventures Holdings Corp. I.

What are the key factors influencing Vaso Corporation's financial results?

Factors such as changes in the IT and healthcare industries, competitive technology and products, medical insurance reimbursement policies, manufacturing or supplier problems, and regulatory actions can influence Vaso Corporation's financial performance.

What are the closing conditions for the proposed business combination with Achari Ventures Holdings Corp. I?

The closing of the proposed business combination between Vaso Corporation and Achari Ventures Holdings Corp. I is subject to various customary closing conditions, including the filing and effectiveness of a Registration Statement on Form S-4, SEC clearance of proxy statements, and approval by the stockholders of both companies.

How does Vaso Corporation ensure transparency and compliance in its business combination process?

Vaso Corporation engages advisors such as Ladenburg Thalmann & Co. Inc. for financial counsel and Katten Muchin Rosenman LLP for legal advice to ensure transparency, compliance, and smooth execution of its business combination with Achari Ventures Holdings Corp. I.

VASO CORPORATION

OTC:VASO

VASO Rankings

VASO Stock Data

22.82M
97.10M
44.66%
Health Information Services
Healthcare
Link
United States of America
Plainview